title: A novel NSAID derivative, phospho-ibuprofen, prevents AOM-induced colon             cancer in rats.
abstract: The cancer chemopreventive properties and gastrointestinal toxicity of ibuprofen are well documented. Modification of existing NSAIDs has improved on the chemopreventive efficacy of this agent and reduced its toxicity. In this study, ibuprofen and a modified derivative (phospho-modified ibuprofen or p-ibuprofen) were used in a chemically induced model of colon cancer. Fisher 344 rats were injected with azoxymethane then treated with either ibuprofen (500 ppm) or p-ibuprofen (900 ppm) for 20 weeks to observe aberrant crypt foci (ACF) or 40 weeks to evaluate tumor incidence and multiplicity. β-catenin and p65 were measured in colonic tissues by immunofluorescence staining. Equal molar doses of ibuprofen (75 and 670 mg/kg) and p-ibuprofen (135 and 1,215 mg/kg) were administered to rats for 7 days to assess acute toxicity. The in vitro effect of p-ibuprofen on COX-2 and PGE(2) synthesis, β-catenin expression and NF-κB activity were examined in RAW 264.7 macrophage and HCT 116 colon cancer cells. At week 20, p-ibuprofen and ibuprofen significantly reduced the multiplicity of ACF compared with control (p<0.05); 31.2 and 37.9%, respectively. At week 40, p-ibuprofen and ibuprofen reduced the multiplicity of colon tumors compared with control (p<0.01) by 47.2 and 56.6%, respectively. Equal molar concentrations of ibuprofen (670 mg/kg) and p-ibuprofen (1,215 mg/kg) resulted in stomach ulceration in 85.7% (6 out of 7) and 14.3% (1 out of 7) of rats, respectively, with p<0.01. Immunofluoresence staining and western blot analysis demonstrated that both ibuprofen and p-ibuprofen suppressed β-catenin nuclear translocation in colon cancer cells. In addition, p-ibuprofen but not ibuprofen inhibited NF-κB activation in colon cancer cells. Collectively, these results suggest that p-ibuprofen is a potential effective novel drug for long-term use in colon cancer prevention.
authors.affiliation: Division of Cancer Prevention, Department of Medicine, Stony                     Brook University, Stony Brook, NY 11794-8175, USA.
authors.forename: Nengtai
authors.initials: N
authors.lastname: Ouyang
authors.forename: Ping
authors.initials: P
authors.lastname: Ji
authors.forename: Jennie L
authors.initials: JL
authors.lastname: Williams
mesh_terms: D058739:Aberrant Crypt Foci / Q000139:chemically induced / Q000188:drug therapy / Q000473:pathology; D000818:Animals; D016588:Anticarcinogenic Agents / Q000008:administration & dosage; D001397:Azoxymethane / Q000633:toxicity; D002273:Carcinogens / Q000633:toxicity; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000473:pathology; D015972:Gene Expression Regulation, Neoplastic / Q000187:drug effects; D045325:HCT116 Cells; D006801:Humans; D007052:Ibuprofen / Q000008:administration & dosage / Q000031:analogs & derivatives*; D016328:NF-kappa B / Q000235:genetics / Q000378:metabolism*; D009374:Neoplasms, Experimental / Q000139:chemically induced / Q000473:pathology / Q000517:prevention & control*; D010755:Organophosphates / Q000008:administration & dosage*; D051381:Rats; D051176:beta Catenin / Q000378:metabolism
chemical_list: C559491:2-(4-isobutylphenyl)propionic acid 4-(diethoxyphosphoryloxy)butyl ester; D016588:Anticarcinogenic Agents; D002273:Carcinogens; D016328:NF-kappa B; D010755:Organophosphates; D051176:beta Catenin; D001397:Azoxymethane; D007052:Ibuprofen